Catalyst Event
GC Cell Corporation (144510) · Earnings Release
From KRX Bio Technology Transfer Index (KBIOTT)
3/16/2026, 12:00:00 AM
Announced full-year 2025 earnings results, reporting a significant increase in net loss to KRW 272.9 billion from KRW 73.9 billion in the previous year. Basic loss per share widened to KRW 18,158 from KRW 4,918.
Korean Translation
2025년 연간 실적 발표. 순손실이 전년 739억원에서 2,729억원으로 크게 증가했으며, 주당순손실은 4,918원에서 18,158원으로 확대됨.
Related Recent Events
D&D Pharmatech Inc (347850) · Other
Top-line results from the Phase 2 clinical trial of MASH treatment candidate DD01, including 48-week liver biopsy data, are scheduled to be announced around May 2026. High importance is estimated due to the potential for significant price impact (≥10%) upon the release of Phase 2 clinical trial results scheduled
5/31/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
The 14th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
The 103rd Annual General Meeting to approve FY2025 financial statements and a cash dividend of KRW 600 per common share on March 20, 2026, with minimal market impact anticipated, is scheduled.
3/20/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
Presentation of preclinical results for two next-generation BCMA-targeting ADC candidates at the AACR Annual Meeting scheduled. Expected impact is Medium as major conference presentations typically influence biotech valuations.
3/18/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
In its 2025 annual report filed on March 18, 2026, the company removed its '1 Product, 1 Trillion KRW Sales' slogan, shifting its strategic focus to fostering multiple global blockbuster drugs; low market impact from strategic shift is expected.
3/18/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a shareholder return plan on March 16, 2026, to be proposed at the March 31 AGM, including the cancellation of 85,316 treasury shares and a record-high cash dividend; expected to cause a >10% price impact due to significant shareholder value enhancement expected.
3/16/2026, 12:00:00 AM